Marinus Pharmaceuticals (NASDAQ:MRNS) Given “Neutral” Rating at HC Wainwright

Marinus Pharmaceuticals (NASDAQ:MRNS)‘s stock had its “neutral” rating reissued by research analysts at HC Wainwright in a research report issued to clients and investors on Thursday,Benzinga reports. They currently have a $2.00 target price on the biopharmaceutical company’s stock.

MRNS has been the topic of several other reports. LADENBURG THALM/SH SH cut shares of Marinus Pharmaceuticals from a “buy” rating to a “neutral” rating in a report on Wednesday, August 14th. StockNews.com began coverage on shares of Marinus Pharmaceuticals in a research note on Sunday. They set a “hold” rating on the stock. TD Cowen reaffirmed a “hold” rating on shares of Marinus Pharmaceuticals in a research note on Friday, October 25th. EF Hutton Acquisition Co. I upgraded Marinus Pharmaceuticals to a “strong-buy” rating in a report on Monday, September 30th. Finally, Royal Bank of Canada lowered their price objective on Marinus Pharmaceuticals from $3.00 to $1.00 and set a “sector perform” rating on the stock in a report on Friday, October 25th. Nine research analysts have rated the stock with a hold rating, two have issued a buy rating and one has issued a strong buy rating to the company’s stock. Based on data from MarketBeat.com, the company has a consensus rating of “Hold” and a consensus target price of $4.79.

Marinus Pharmaceuticals Stock Performance

Marinus Pharmaceuticals stock opened at $0.30 on Thursday. Marinus Pharmaceuticals has a 52 week low of $0.26 and a 52 week high of $11.26. The firm has a market capitalization of $16.65 million, a price-to-earnings ratio of -0.12 and a beta of 1.26. The company has a 50 day moving average price of $1.28 and a 200 day moving average price of $1.34.

Marinus Pharmaceuticals (NASDAQ:MRNS) last issued its earnings results on Tuesday, November 12th. The biopharmaceutical company reported ($0.42) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.44) by $0.02. The company had revenue of $8.54 million for the quarter, compared to the consensus estimate of $8.95 million. Marinus Pharmaceuticals had a negative return on equity of 7,831.35% and a negative net margin of 446.48%. Equities analysts forecast that Marinus Pharmaceuticals will post -1.92 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently made changes to their positions in MRNS. Hussman Strategic Advisors Inc. raised its position in Marinus Pharmaceuticals by 14.3% in the second quarter. Hussman Strategic Advisors Inc. now owns 84,000 shares of the biopharmaceutical company’s stock worth $98,000 after purchasing an additional 10,500 shares in the last quarter. AQR Capital Management LLC grew its stake in shares of Marinus Pharmaceuticals by 70.3% in the 2nd quarter. AQR Capital Management LLC now owns 31,333 shares of the biopharmaceutical company’s stock valued at $37,000 after purchasing an additional 12,934 shares during the period. Point72 DIFC Ltd bought a new stake in shares of Marinus Pharmaceuticals in the 2nd quarter valued at approximately $28,000. SG Americas Securities LLC acquired a new position in shares of Marinus Pharmaceuticals in the 2nd quarter worth approximately $34,000. Finally, Jacobs Levy Equity Management Inc. bought a new position in shares of Marinus Pharmaceuticals during the 1st quarter worth approximately $384,000. Institutional investors own 98.80% of the company’s stock.

About Marinus Pharmaceuticals

Marinus Pharmaceuticals, Inc, a pharmaceutical company, focuses on development and commercialization of therapeutic products for patients suffering from rare genetic epilepsies and other seizure disorders. It offers ZTALMY (ganaxolone), an oral suspension for the treatment of seizures associated with cyclin-dependent kinase-like 5 deficiency disorder for adult and pediatric patient populations in acute and chronic care, and in-patient and self-administered settings.